PVH Cuts Outlook After Iran War Hits Sales

PVH Cuts Outlook after weaker EMEA demand from the Iran war; first-quarter showed operational progress, but shares plunged, forcing traders to reprice.

June 04, 2026·2 min read
View all news articles
Mannequin under a dimming spotlight on a slate-ice gradient illustrating PVH Cuts Outlook and weakened EMEA retail demand.

KEY TAKEAWAYS

  • Full-year 2026 revenue now expected approximately flat, down from prior slight growth.
  • Company attributed the revision to weaker EMEA consumer demand tied to the Iran war.
  • Shares fell about 24% after the guidance cut, despite first-quarter operational progress and direct-to-consumer growth.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

PVH Corp. (NYSE: PVH) said in a press release on June 3, 2026, that it lowered its full-year 2026 revenue forecast to approximately flat from a prior expectation of slight growth. The revision reflects weaker demand linked to the Iran war in the Europe, Middle East, and Africa (EMEA) region, even as the company reported first-quarter results and maintained expectations for improved profitability.

PVH Lowers 2026 Outlook Amid Regional Demand Pressure

PVH, owner of Calvin Klein and TOMMY HILFIGER, attributed the reduced revenue outlook to the impact of the Middle East conflict on consumer demand, with the most significant pressure in EMEA. The company framed the update in a press release titled "PVH Corp. Reports 2026 First Quarter Results and Updates Full Year Outlook" issued on June 3.

Management emphasized operational progress despite the top-line challenges. The narrower revenue forecast reflects a strategic focus on protecting margins amid external shocks to demand.

First-Quarter Results and Profitability Expectations

The release reported growth in PVH’s direct-to-consumer business and progress on operating priorities. Chief Executive Stefan Larsson said, "We delivered on our plan and commitments in the first quarter." The company reiterated its expectation for improved profitability metrics for the full year, highlighting efforts to strengthen its two global brands.

Shares Drop After Guidance Revision

Shares declined about 24% following the outlook cut, reflecting investor sensitivity to geopolitical risks and the Iran war’s effect on sales in key markets. By narrowing the revenue outlook while emphasizing operational gains and profitability focus, PVH signaled a priority on margin stability over near-term revenue growth amid the regional disruption.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Cerebras Stock Climbs After Wall Street Buy Calls

Cerebras Stock Climbs After Wall Street Buy Calls

Cerebras stock rallied after nine brokerages initiated coverage on June 8, 2026, supporting a near-term rerating as analysts cited wafer-scale chips.

Intel Stock Surges on Reported Google, Nvidia Foundry Deals

Intel Stock Surges on Reported Google, Nvidia Foundry Deals

Intel stock surges after reports of Google TPU orders and Nvidia tests of Intel's advanced process; lack of filings raises verification risk for traders.

SanDisk Stock Climbs Then Pulls Back After Upgrades

SanDisk Stock Climbs Then Pulls Back After Upgrades

SanDisk stock drew June 8 analyst 12-month target lifts after an April blockbuster quarter; traders weigh May AI gains versus NAND supply concerns.

Ingredion Tate & Lyle Takeover Agreed

Ingredion Tate & Lyle Takeover Agreed

Ingredion Tate & Lyle takeover is an all-cash $3.6 billion offer that preserves dividends, wins 17.1% undertakings and tightens near-term deal certainty.

Amazon Corning Fiber-Optic Deal Adds North Carolina Jobs

Amazon Corning Fiber-Optic Deal Adds North Carolina Jobs

Amazon Corning fiber-optic deal expands U.S. manufacturing and adds 1,000 jobs while positioning Corning as a supplier for Amazon's data centers.

Roche Nurix Deal Advances BTK Program

Roche Nurix Deal Advances BTK Program

Roche Nurix deal sets U.S. co-commercialization and outlines near-term clinical catalysts, with material deal economics that matter to biotech investors.